The short answer is no, sotorasib does not have efficacy in KRAS mutant tumors beyond KRAS G12C. KRAS activates downstream signaling by actively cycling from GTP to GDP, and exists in both GTP and GDP states. The cysteine residue at the covalent binding pocket under switch II in the inactive GDP sta...